Liver protection of CACA technical guidelines for holistic integrative management of cancer

Ningning Zhang, Lungen Lu, Baoshan Cao, Yanjing Gao, Feng Han, Liangping Li, QiJiong Li, Shuchen Li, Xiaowu Li, Jingfeng Liu, Yefu Liu, Yingqian Lv, Yongzhan Nie, Xizhong Shen, Dongde Wu, Qiang Wu, Jun Xu, Liping Yao, Yuzheng Zhuge, Xiu-Bao Ren, Dean Tian, Guohong Han, Wei Lu, Yonglin Bai, Haining Fan Xiaobing Chen, Yingbin Hu, Weidong Jia, Zuoyi Jiao, Yongdong Jin, Duo Li, Runmei Li, Wenxin Li, Xiangcheng Li, Yue Li, Zhiwei Li, Jing Liang, T.‐s. Lin, Taotao Liu, Liang Ma, Jianxin Meng, Tao Peng, Chengyi Sun, Zhiqiang Sun, Hongwei Wang, Lu Wang, Shunxiang Wang, Yusheng Wang, Jun Rao, Limin Xia, Yonghui Xia, Qing Xie, Tao Xin, Jianhua Xu, Liang Xu, Qi Xu, Yan Dong, Changqing Yang, Jin‐Hui Yang, Jianhua Yi, Yongxiang Yi, Lan Yu, Songning Yu, Liaoyun Zhang, Yue Zhao, Hong Zhu, Hui ZhuangHolistic 2025 · DOI

Abstract

Antitumor treatments, including chemotherapy, targeted therapy, immunotherapy, surgery, and radiotherapy, are essential in cancer care but frequently carry the risk of liver injury. Such complications can severely impact patient prognosis and quality of life. To address this, the Oncology Hepatology Committee of the China Anti-Cancer Association (CACA) has developed comprehensive technical guidelines for the holistic management of liver protection. These guidelines synthesize the latest research and clinical experience to provide standardized protocols for the diagnosis, prevention, and treatment of treatment-related liver injury.

Introduction: The Challenge of Hepatotoxicity in Oncology

Liver injury is a frequent and severe complication of modern cancer therapy. Whether caused by the direct chemical toxicity of chemotherapy, the immune-mediated inflammation of checkpoint inhibitors, or the physical trauma of surgery and radiation, hepatotoxicity often forces the suspension or discontinuation of life-saving treatments.

The challenge is twofold: first, the clinical impact of treatment interruption directly worsens patient prognosis; second, the mechanisms of injury vary wildly across different modalities. Historically, management has been fragmented. The CACA guidelines bridge this gap, advocating for a "holistic integrative" approach that treats liver protection as an integral component of the overall oncological strategy.

Standardized Severity Grading

A cornerstone of effective management is the objective assessment of injury severity. The guidelines adopt the Common Terminology Criteria for Adverse Events (CTCAE) 5.0 framework to establish clear thresholds for biochemical markers like serum bilirubin and AST/ALT levels.

Table 1: Severity grading of chemotherapy-induced liver injury (CILI) based on CTCAE 5.0.

These grades (G1 to G5) serve as the basis for clinical decision-making, determining when a treatment can safely continue and when it must be paused or permanently halted. For example, clear biochemical markers like ALT > 8x ULN are established as thresholds for stopping potentially hepatotoxic drugs.

Management of Immune-Mediated Hepatitis (IMH)

With the rise of Immune Checkpoint Inhibitors (ICIs), clinicians face a unique form of liver injury: immune-mediated hepatitis. Unlike traditional drug toxicity, IMH results from enhanced immune activity rather than direct chemical damage. The CACA guidelines provide specific, tiered recommendations for monitoring and intervention based on the severity grade.

Table 2: Clinical recommendations for the treatment and monitoring of ICI-induced liver injury.

As shown in the recommendations, while G1 injury allows for continued therapy with increased monitoring (1–2 times per week), G4 injury necessitates the permanent discontinuation of immunotherapy and daily monitoring.

Key Clinical Insights

Hepatitis Reactivation

A critical safety measure highlighted in the guidelines is mandatory screening for Hepatitis B (HBV) and Hepatitis C (HCV) before initiating targeted or immunotherapy. These treatments can reactivate latent viruses, potentially leading to acute, life-threatening liver failure.

Surgical and Radiation Safety

For local treatments, the guidelines define "safe volume" parameters for hepatectomy using Standardized Liver Volume (SLV). In radiotherapy, they establish dosage limits—such as keeping the average liver dose below 28-32 Gy for primary hepatocellular carcinoma—to prevent Radiation-Induced Liver Disease (RILD).

Pharmacological Toolkit

The guidelines recommend a tailored pharmacological approach using specific agents based on the injury type, including antioxidants (Bicyclol), anti-inflammatories (Glycyrrhizic acid), and membrane stabilizers (Polyene phosphatidylcholine).

Conclusion and Future Directions

The CACA technical guidelines provide a vital roadmap for clinicians to navigate the complexities of liver protection in cancer care. However, the authors note that further research is needed to refine these protocols. Areas for future work include validating the RUCAM scale specifically for chemotherapy-induced injury, refining the "time window" for advanced interventions like artificial liver support, and elucidating the molecular pathways of targeted therapy-induced hepatotoxicity.

Summary updated

Abstract

Abstract Background Antitumor drugs (such as chemotherapy, targeted therapy, immunotherapy, etc.) and local treatments like surgery and radiotherapy are widely used in cancer treatment, but they often carry the risk of liver injury, which seriously affects the prognosis and quality of life of patients. Therefore, liver protection is of crucial importance in cancer treatment. Methods Relevant experts organized by the Oncology Hepatology Committee of China Anti-Cancer Association Association formulated this guideline based on the latest research achievements and clinical practice experience at home and abroad, aiming to provide comprehensive and systematic guidance for clinicians on liver protection. Results This guideline elaborates on the importance of liver protection during cancer treatment, comprehensively introduces the pathophysiological mechanisms, diagnosis, treatment, and preventive measures of antitumor treatment-related liver injury. Conclusion This guideline is helpful for clinicians to formulate individualized treatment plans, improve the treatment outcome and quality of life of cancer patients, and provides an important reference for the clinical practice of liver protection in cancer treatment.
BibTeX
@inproceedings{zhang2025liver,
  author = {Ningning Zhang and Lungen Lu and Baoshan Cao and Yanjing Gao and Feng Han and Liangping Li and QiJiong Li and Shuchen Li and Xiaowu Li and Jingfeng Liu and Yefu Liu and Yingqian Lv and Yongzhan Nie and Xizhong Shen and Dongde Wu and Qiang Wu and Jun Xu and Liping Yao and Ning Zhang and Yuzheng Zhuge and Xiu-Bao Ren and Dean Tian and Guohong Han and Wei Lu and Yonglin Bai and Haining Fan Xiaobing Chen and Yingbin Hu and Weidong Jia and Zuoyi Jiao and Yongdong Jin and Duo Li and Runmei Li and Wenxin Li and Xiangcheng Li and Yue Li and Zhiwei Li and Jing Liang and T.‐S. LIN and Taotao Liu and Liang Ma and Jianxin Meng and Tao Peng and Chengyi Sun and Zhiqiang Sun and Hongwei Wang and Lu Wang and Shunxiang Wang and Yusheng Wang and Jun Rao and Limin Xia and Yonghui Xia and Qing Xie and Tao Xin and Jianhua Xu and Liang Xu and Qi Xu and Yan Dong and Changqing Yang and Jin‐Hui Yang and Jianhua Yi and Yongxiang Yi and Lan Yu and Songning Yu and Liaoyun Zhang and Yue Zhao and Hong Zhu and Hui Zhuang},
  title = {{Liver protection of CACA technical guidelines for holistic integrative management of cancer}},
  booktitle = {Holistic},
  year = {2025},
  doi = {10.1007/s44178-025-00157-5},
}
Figure